혈전 관리 기기 세계 시장 규모는 2024년 19억 달러에 달했습니다. IMARC Group은 이 시장이 2033년까지 29억 달러에 달하고, 2025-2033년까지 4.58%의 연평균 복합 성장률(CAGR)을 보일 것으로 전망하고 있습니다. 현재 북미가 시장을 독점하고 있으며, 2024년에는 55.3% 이상의 큰 시장 점유율을 차지할 것으로 예측됩니다. 심혈관 질환의 유병률 증가, 인구 고령화, 최소 침습 수술에 대한 수요 증가, 기술 발전 등이 혈전 관리 기기 시장 점유율을 높이는 주요 요인으로 작용하고 있습니다.
혈전 관리 기기 시장은 심부정맥 혈전증, 심혈관 질환, 뇌졸중, 폐색전증의 유병률 증가로 인해 효과적인 혈전 제거 솔루션에 대한 수요가 증가하고 있습니다. 혈전성 질환에 걸리기 쉬운 노년층이 빠르게 증가하고 있는 것도 시장을 더욱 활성화시키고 있습니다. 저침습적 시술 기술의 발전으로 입원 기간과 회복 기간이 단축되어 환자의 예후가 개선됩니다. 혈전 조기 발견 및 치료에 대한 인식이 높아지면서 혈전 조기 발견 및 치료에 대한 인식이 높아진 것이 채택을 촉진하고 있습니다. 또한, 의료비 지출 증가, 첨단 의료 기술에 대한 정부 지원, 전문 치료 센터의 확대도 시장 성장에 기여하고 있습니다. 또한, 주요 의료기기 제조업체의 존재와 혁신적인 혈전 제거 기술에 대한 연구가 진행되고 있는 것도 업계경쟁 구도를 부추기고 있습니다.
미국 혈전 관리 기기 시장은 심부정맥 혈전증, 심혈관 질환, 폐색전증의 높은 유병률에 의해 주도되고 있습니다. 선진화된 의료 인프라, 저침습적 시술의 도입 증가, 대형 의료기기 제조업체의 존재감이 시장 성장에 기여하고 있습니다. 유리한 상환 정책과 높은 의료비 지출로 인해 첨단 치료에 대한 접근성이 향상되고 있습니다. 또한, 혈전 조기 발견에 대한 인식 증가, 고령자 증가, 혈전 제거 장치의 기술 발전이 수요를 촉진하고 있습니다. 예를 들어, 2025년 1월, Argon Medical Devices는 폐색전증(PE) 진단을 받은 환자의 폐에서 혈전을 제거하는 Cleaner Pro 혈전 제거 시스템의 안전성과 유효성을 평가하는 CLEAN-PE 검사의 첫 환자 등록을 보고했습니다. CLEAN-PE에는 미국 내 여러 병원에서 100명 이상의 환자가 등록될 것으로 예측됩니다. 정부 지원, 지속적인 연구 개발, 외래 수술 증가는 미국 시장 확대를 더욱 촉진하고 있습니다.
심혈관 질환 및 혈전성 질환의 유병률 상승
심혈관 질환, 뇌졸중, 심부정맥혈전증, 폐색전증의 발병률 증가는 혈전 관리 기기 시장의 주요 촉진요인입니다. 좌식 생활습관, 비만, 흡연, 고혈압이 혈전증 환자 증가에 기여하고 있어 효과적인 치료 솔루션이 필요합니다. 전 세계 인구의 고령화는 혈전성 질환의 위험을 더욱 증가시켜 첨단 혈전 제거 기술에 대한 수요를 증가시키고 있습니다. 최근 산업 보고서에 따르면, 2024년 세계 인구의 12%가 60세 이상이며, 이는 12억 명에 해당합니다. 이 숫자는 2050년까지 21억 명으로 증가하여 세계 총인구의 26%를 차지할 것으로 예측됩니다. 조기 진단과 조기 개입에 대한 인식이 높아짐에 따라 병원과 전문 클리닉에서 혈전 관리 기기의 도입이 증가하고 있습니다. 이러한 질병 부담 증가는 혁신적인 혈전 제거 기술의 연구개발과 상용화를 촉진하고 있습니다.
혈전 관리 기기의 기술적 진보
경피적 혈전 제거 시스템, 카테터 직접 혈전 용해 요법, 기계적 혈전 제거 장치 등 현재 진행 중인 혈전 관리 기기의 기술 혁신은 환자 치료에 혁명을 불러일으키고 있습니다. 이러한 발전으로 인해 최소 침습적 시술이 가능해져 회복 시간과 입원 기간을 단축하고 환자의 예후를 개선할 수 있게 되었습니다. 최신 혈전 제거 장비는 정확성과 효율성을 향상시켜 보다 안전하고 효과적인 시술을 가능하게 합니다. 인공지능, 로봇 공학, 실시간 영상은 혈전 제거 기술의 향상에 더욱 기여하고 있습니다. 의료 서비스 제공업체들이 더 나은 더 빠른, 더 안전한 치료법을 찾고 있는 가운데, 지속적인 제품 개발과 규제 당국의 승인은 첨단 혈전 관리 기술의 채택을 촉진하고 있습니다. 예를 들어, 2024년 9월 말초 정맥 혈전 제거를 목적으로 하는 CLEANER VacTM Thrombectomy System이 중재적 방사선, 혈관 수술, 중재적 심장학, 종양학 시술을 위한 의료기기 솔루션의 의료기기 솔루션의 주요 공급업체인 Argon Medical Devices에서 발표되었습니다. CLEANER Vac Thrombectomy System이라는 일회용 대구경 흡입 도구는 혈류가 제한된 정맥에서 혈전이라고 알려진 혈전을 빠르고 효과적으로 제거하기 위해 개발되었습니다.
우호적인 헬스케어 정책 및 환급 지원
정부의 지원책과 상환 체계는 첨단 혈전 관리 치료의 접근성을 높임으로써 혈전 관리 기기 시장의 긍정적인 전망을 만들어내고 있습니다. 미국을 포함한 많은 국가에서 혈전제거술에 유리한 보험 적용을 제공하고 있으며, 더 많은 병원과 의료 서비스 제공업체가 이러한 기술을 채택하도록 장려하고 있습니다. FDA 등 규제 당국의 승인과 새로운 혈전 관리 기기에 대한 CE 마크 인증은 시장 확대에 더욱 박차를 가할 것입니다. 예를 들어, 2023년 3월, Penumbra는 획기적인 동맥 혈전 제거 시스템인 Lightning Bolt 7의 도입에 대해 식품의약국으로부터 승인을 받았습니다. 이 기술은 압력 센서와 알고리즘을 채택하여 장치가 혈액을 흡입하고 있는지 혈전을 흡입하고 있는지 판단하고 흡입량을 조절하여 혈전을 제거합니다. 페난브라(본사: 캘리포니아주 알라메다)는 라이트닝 볼트 7과 최근 출시된 라이트닝 플래시로 인해 2023년 매출이 23%에서 25% 증가할 것으로 예상하고 있습니다. 또한, 의료 지출 증가와 의료 인프라에 대한 투자는 제조업체가 혁신적인 혈전 관리 솔루션을 도입할 수 있는 기회를 창출하고, 생명을 구할 수 있는 치료법에 대한 광범위한 환자 접근성을 보장합니다.
The global clot management devices market size was valued at USD 1.90 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 2.90 Billion by 2033, exhibiting a CAGR of 4.58% during 2025-2033. North America currently dominates the market, holding a significant market share of over 55.3% in 2024. The rising prevalence of cardiovascular diseases, an aging population, increasing demand for minimally invasive procedures, and technological advancements are some of the key factors fueling the clot management devices market share.
The market for clot management devices is driven by the rising prevalence of deep vein thrombosis, cardiovascular diseases, stroke, and pulmonary embolism, which increase the demand for effective clot removal solutions. A rapidly increasing geriatric population, more susceptible to thrombotic disease, fuels the market further. Advances in technology for minimally invasive procedures improve patient outcomes with shorter hospital stays and recovery periods. Greater awareness of early detection and treatment of clots and favorable reimbursement practices drive adoption. Additionally, rising healthcare expenditures, government support for advanced medical technologies, and the expansion of specialized treatment centers contribute to market growth. The presence of key medical device manufacturers and ongoing research into innovative thrombectomy techniques also drive the industry's competitive landscape.
The market for clot management devices in the United States is driven by the high prevalence of deep vein thrombosis, cardiovascular diseases, and pulmonary embolism. The country's advanced healthcare infrastructure, increasing adoption of minimally invasive procedures, and strong presence of leading medical device manufacturers contribute to market growth. Favorable reimbursement policies and high healthcare spending enhance access to advanced treatments. Additionally, rising awareness about early clot detection, a growing geriatric population, and technological advancements in thrombectomy devices fuel demand. For instance, in January 2025, Argon Medical Devices reported the initial patient enrollment in the CLEAN-PE study, which seeks to assess the safety and effectiveness of the Cleaner Pro thrombectomy system for extracting blood clots from the lungs of patients diagnosed with pulmonary embolism (PE). It is anticipated that more than 100 patients are enrolled in CLEAN-PE at different hospitals throughout the United States. Government support, ongoing research and development, and an increasing number of outpatient procedures further propel the market's expansion in the U.S.
Rising Prevalence of Cardiovascular Diseases and Thrombotic Disorders
The increasing incidence of cardiovascular diseases, stroke, deep vein thrombosis, and pulmonary embolism is a major driver of the clot management devices market. Sedentary lifestyles, obesity, smoking, and hypertension contribute to higher cases of blood clots, necessitating effective treatment solutions. An aging global population further escalates the risk of thrombotic disorders, increasing demand for advanced clot removal technologies. According to recent industry reports, in 2024, 12% of the global population was aged 60 years and above, equating to 1.2 Billion individuals. This number is expected to rise to 2.1 Billion by 2050, making up 26% of the total population in the world. The growing awareness about early diagnosis and intervention has led to higher adoption of clot management devices in hospitals and specialized clinics. This rising disease burden continues to push the research, development, and commercialization of innovative clot removal technologies.
Technological Advancements in Clot Management Devices
Ongoing innovations in clot management devices, such as percutaneous thrombectomy systems, catheter-directed thrombolysis, and mechanical thrombectomy devices, are revolutionizing patient care. These advancements allow for minimally invasive procedures, reducing recovery time and hospital stays while improving patient outcomes. Modern thrombectomy devices offer enhanced precision and efficiency, making procedures safer and more effective. Artificial intelligence, robotics, and real-time imaging further contribute to improved clot removal techniques. As healthcare providers seek better, faster, and safer treatment options, continuous product development and regulatory approvals drive the adoption of advanced clot management technologies. For instance, in September 2024, The CLEANER VacTM Thrombectomy System, which is intended to remove blood clots from the peripheral venous vasculature, was introduced by Argon Medical Devices, a leading provider of medical device solutions for interventional radiology, vascular surgery, interventional cardiology, and oncology procedures. A single-use, large-bore aspiration tool called the CLEANER Vac Thrombectomy System was developed to quickly and effectively remove blood clots, also known as thrombus, from veins with restricted blood flow.
Favorable Healthcare Policies and Reimbursement Support
Supportive government policies and reimbursement frameworks create a positive clot management devices market outlook by making advanced clot management treatments more accessible. Many countries, including the United States, offer favorable insurance coverage for thrombectomy procedures, encouraging more hospitals and healthcare providers to adopt these technologies. Regulatory approvals from agencies like the FDA and CE mark certification for new clot management devices further drive market expansion. For instance, in March 2023, Penumbra received approval from the Food and Drug Administration to introduce Lightning Bolt 7, a revolutionary arterial thrombectomy system. The technology employs pressure sensors and an algorithm to determine whether the device is pulling in blood or a clot and modulates aspiration to remove blood clots. Penumbra, situated in Alameda, California, anticipates a 23% to 25% increase in sales in 2023 due to the Lightning Bolt 7 product and the recent introduction of Lightning Flash, another vascular device. Additionally, increasing healthcare expenditures and investments in medical infrastructure create opportunities for manufacturers to introduce innovative clot management solutions, ensuring broader patient access to life-saving treatments.
Percutaneous thrombectomy devices stand as the largest product type in 2024, holding around 37.6% of the market due to their effectiveness in rapidly removing blood clots with minimal invasiveness. These devices are widely used in treating deep vein thrombosis, pulmonary embolism, and arterial thrombosis, reducing the risk of complications and improving patient outcomes. Advancements in technology have enhanced their precision and efficiency, making them a preferred choice among healthcare professionals. Additionally, the growing prevalence of cardiovascular diseases, an aging population, and increasing demand for faster recovery times further drive their adoption. Their ability to minimize hospital stays and healthcare costs also boosts market growth.
Hospitals leads the market with around 80.9% of market share in 2024 due to their advanced infrastructure, skilled healthcare professionals, and ability to handle complex thrombectomy procedures. They offer a wide range of clot management treatments, including percutaneous thrombectomy, catheter-directed thrombolysis, and surgical thrombectomy, ensuring comprehensive patient care. The increasing prevalence of cardiovascular diseases and emergency cases requiring immediate clot removal further drive demand. Additionally, hospitals have better access to cutting-edge medical technologies and government funding, enhancing treatment efficiency. The rising number of hospital admissions for thrombotic disorders and the availability of reimbursement policies also contribute to their market dominance.
In 2024, North America accounted for the largest market share of over 55.3%. The clot management devices demand in North America is influenced by the high prevalence of cardiovascular diseases, stroke, deep vein thrombosis, and pulmonary embolism. The region's advanced healthcare infrastructure, strong presence of key medical device manufacturers, and increasing adoption of minimally invasive procedures contribute to market growth. Favorable reimbursement policies, high healthcare spending, and government support for advanced medical technologies further enhance accessibility. Additionally, rising awareness of early clot detection and treatment, coupled with a growing geriatric population prone to thrombotic disorders, fuels demand. Technological advancements and an increasing number of outpatient procedures also play a significant role.
United States Clot Management Devices Market Analysis
In 2024, the United States accounted for over 89.80% of the clot management devices market in North America. The United States clot management devices market is primarily driven by the rising incidence of cardiovascular diseases, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke, driven by an increasing geriatric population and growing obesity rates. According to the Population Reference Bureau, the number of individuals aged 65 and above in the United States will reach 82 million by 2050, accounting for 23% of the population of the country. Moreover, the prevalence of atrial fibrillation, a key risk factor for thromboembolic events, is also rising, propelling the need for advanced clot removal solutions. Technological advancements in thrombectomy and embolectomy devices, such as catheter-directed thrombolysis and aspiration thrombectomy, are also improving procedural efficiency and patient outcomes, fueling adoption in hospitals and ambulatory surgical centers. Additionally, the growing preference for minimally invasive procedures over conventional surgical interventions is further contributing to industry expansion, as these devices reduce complications, hospital stays, and recovery times. Favorable reimbursement policies and guidelines from organizations such as the American Heart Association (AHA) and the U.S. Food and Drug Administration (FDA) further support the adoption of innovative clot management technologies. Besides this, expanding clinical research on novel clot management approaches is expected to further propel industry advancements.
Asia Pacific Clot Management Devices Market Analysis
The Asia Pacific clot management devices market is growing due to rising cases of atrial fibrillation and hypertension, both significant risk factors for thromboembolic disorders. Moreover, the increasing prevalence of cardiovascular diseases and venous thromboembolism (VTE), driven by aging populations, rising urbanization, and lifestyle-related risk factors such as diabetes, is also propelling the market. According to industry reports, 52.9% of the total population of Asia lived in urban areas in 2024, equating to 2,545,230,547 individuals. Additionally, rising awareness about stroke prevention and early treatment, driven by national health programs, is also encouraging the adoption of advanced clot removal technologies. Furthermore, the expansion of private healthcare facilities and the increasing presence of multinational medical device companies in emerging markets are improving access to cutting-edge thrombectomy and embolectomy solutions. Growing disposable incomes and improved insurance coverage are also making high-cost clot management procedures more accessible, supporting overall market growth.
Europe Clot Management Devices Market Analysis
The Europe clot management devices market is experiencing growth, fueled by the increasing prevalence of thromboembolic disorders, driven by aging demographics and sedentary lifestyles. The growing burden of non-communicable diseases, including hypertension, diabetes, and cardiovascular disorders, further elevates the risk of thromboembolic events. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) account for more than 42.5% of all deaths each year in Europe, making them the leading cause of premature death in the region. The widespread implementation of national stroke prevention programs and guidelines by organizations such as the European Society of Cardiology (ESC) and the European Stroke Organisation (ESO) is driving the adoption of advanced thrombectomy and thrombolysis devices. Increasing healthcare investments across Europe, particularly in digital health integration and AI-powered clot detection technologies, is further improving diagnosis and treatment precision. Additionally, the rising number of stroke centers and specialized vascular care units across countries such as Germany, the UK, France, and Italy is also boosting demand for advanced clot management technologies. Increasing awareness campaigns and training programs for healthcare professionals on thromboembolic disease management are further driving adoption. The rise in surgical procedures, particularly orthopedic and cancer-related surgeries, is also leading to a higher incidence of post-operative blood clots, propelling the need for effective clot management solutions.
Latin America Clot Management Devices Market Analysis
The Latin America clot management devices market is expanding due to the increasing prevalence of hypertension and metabolic disorders, which elevate the risk of thromboembolic events. Growing healthcare expenditure and government initiatives aimed at improving stroke care are enhancing access to advanced thrombectomy and thrombolysis procedures. For instance, as per the International Trade Administration (ITA), 9.47% of the GDP of Brazil is spent on healthcare, making it the largest market for healthcare in Latin America. The expansion of private hospitals and specialized stroke centers, particularly in Brazil, Mexico, and Argentina, is further supporting market growth. According to the ITA, 62% of the hospitals in Brazil are private. Besides this, strengthening regulatory frameworks and faster approval processes are also facilitating the introduction of new clot removal technologies in the region.
Middle East and Africa Clot Management Devices Market Analysis
The Middle East and Africa clot management devices market is propelled by an increasing geriatric population and a higher incidence of risk factors such as hypertension and dyslipidemia, increasing the likelihood of thromboembolic events. Expanding health insurance coverage and government subsidies in countries such as Saudi Arabia and the UAE are improving access to advanced clot removal procedures. For instance, according to the International Trade Administration, the Saudi Arabian government intends to invest more than USD 65 billion under Vision 2030 to build the nation's healthcare system and restructure and privatize insurance and health care. Additionally, local manufacturing initiatives and partnerships with international medical device companies are improving product availability and affordability. Growing medical tourism in the region is further supporting the adoption of advanced clot management technologies.
The market for clot management devices is extremely competitive, and major competitors are concentrating on product improvements, strategic mergers, and technology breakthroughs to improve their market positions. Major companies like Medtronic, Boston Scientific, Terumo Corporation, and Abbott Laboratories dominate the industry with a broad product portfolio and global presence. Startups and mid-sized firms are also entering the market, introducing novel minimally invasive solutions. Collaborations with healthcare providers and research institutions drive innovation. Regulatory approvals, reimbursement policies, and clinical trial success significantly impact market dynamics. Companies compete based on product efficacy, pricing, and distribution networks, making innovation and strategic expansion crucial.